BridgeBio's commercial inflection, driven by Attruby, has propelled revenue from $5.9M in 2024Q4 to $208.5M in 2026Q2 (88.6% YoY growth), with gross margins expanding to 101.8%. However, the company remains deeply unprofitable, with net losses of -$152.2M in 2...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue surged to $208.5M in 2026Q2 (88.6% YoY) with gross margin at 101.8%, yet operating margin remains deeply negative at -51.4% due to elevated R&D ($149.4M) and SG&A ($186.3M) expenses.
Interim Phase 3 FORTIFY trial data for BBP-418 in limb-girdle muscular dystrophy type 2I/R9 met efficacy endpoints, indicating strong clinical progress.
BridgeBio Pharma's Attruby has shown a strong U.S. launch, contributing to favorable competitive dynamics and revenue growth.
Analysts maintain a Buy rating on BBIO, citing strong clinical and commercial performance as key drivers.
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 10, 2026 | -$0.78-35.5% vs -$0.58 | $244M+10.3% vs $221M |
Q2 2026 May 7, 2026 | -$0.84-23.8% vs -$0.68 | $195M+9.2% vs $178M |
Q1 2026 Feb 24, 2026 | -$1.00-40.2% vs -$0.71 | $154M+5.0% vs $147M |
Q4 2025 Oct 29, 2025 | -$0.95-8.0% vs -$0.88 | $121M-18.5% vs $148M |
BridgeBio Pharma NASDAQ: BBIO expects 2027 to be a transformative year as it expands from one commercial product to four globally launched therapies, President and CFO Thomas Trimarchi said during a Bernstein discussion.
BridgeBio Pharma (NASDAQ: BBIO) expects 2027 to be a transformative year as it expands from one commercial product to four globally launched therapies, President and CFO Thomas Trimarchi said during a Bernstein discussion. Trimarchi said the company's strategy centers on developing medicines for genetic diseases with substantial unmet need, particularly where a genetic mechanism can be
BridgeBio Pharma, Inc. (BBIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
- In the first peer-reviewed, real-world, contemporary, comparative effectiveness study of TTR stabilizers in ATTR-CM using U.S. claims data, acoramidis was associated with a statistically and clinically significant 34% reduction in a composite of clinical worsening events (diuretic intensification, heart failure hospitalization, and mortality) versus tafamidis (p=0.046), supporting improved clinical stability of acoramidis over tafamidis
Benchmark BBIO against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for BridgeBio Pharma, Inc. (BBIO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $66.91 | $13.11B | -17.65 | 126.26% | -145.26% | — | — | |
| $110.12 | $9.06B | -29.84 | -16.72% | -285.41% | -21.5% | — | |
| $3.89 | $598.38M | -5.33 | 40.22% | -7.25% | -27.96% | — | |
| $25.23 | $3.17B | -7.67 | -4.26% | -386.32% | -87.98% | — | |
| $286.91 | $8B | -21.28 | -100% | — | -34.15% | — | |
| $506.74 | $128.61B | 33.08 | 9.57% | 34.89% | 23.31% | — |
BridgeBio Pharma, Inc. (BBIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
BridgeBio Pharma, Inc. (BBIO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 17, 2026·SEC
Aug 10, 2026·SEC
Jul 22, 2026·SEC
Get notified when BBIO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BridgeBio Pharma, Inc. (BBIO) stock FAQ — growth, dividends, profitability & financials explained
BridgeBio Pharma, Inc. (BBIO) reported $691.8M in revenue for fiscal year 2025.
BridgeBio Pharma, Inc. (BBIO) grew revenue by 126.3% over the past year. This is strong growth.
BridgeBio Pharma, Inc. (BBIO) reported a net loss of $696.2M for fiscal year 2025.
BridgeBio Pharma, Inc. (BBIO) had negative free cash flow of $592.1M in fiscal year 2025, likely due to heavy capital investments.
